Ex-Regeneron Exec Graham Named Evelo Bio Chief Development Officer

Neil Graham has joined Evelo Biosciences (NASDAQ: [[ticker:EVLO]]) as its chief development officer. He was most recently vice president of immunology and inflammation at Regeneron Pharmaceuticals (NASDAQ: [[ticker:REGN]]). Graham’s experience also includes positions at Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]) and Trimeris. Evelo is developing oral biologic drugs that address the small intestinal axis, which plays a role in the immune, metabolic, and neurological systems. In 2018, the Cambridge, MA-based company raised $85 million from its IPO.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan